Earnings Summary

Neoleukin Therapeutics, Inc.’s revenue jumped NaN% since last year same period to $0Mn in the Q2 2023. On a quarterly growth basis, Neoleukin Therapeutics, Inc. has generated NaN% jump in its revenue since last 3-months.

Neoleukin Therapeutics, Inc.’s net profit jumped 86.71% since last year same period to $-2.09Mn in the Q2 2023. On a quarterly growth basis, Neoleukin Therapeutics, Inc. has generated 85.32% jump in its net profits since last 3-months.

Neoleukin Therapeutics, Inc.’s net profit margin jumped NaN% since last year same period to -Inf% in the Q2 2023. On a quarterly growth basis, Neoleukin Therapeutics, Inc. has generated NaN% jump in its net profit margins since last 3-months.

Neoleukin Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.21 - a 30% jump from last quarter’s estimates.

Neoleukin Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.21.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Neoleukin Therapeutics, Inc.’s return on assets (ROA) stands at -0.23.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Neoleukin Therapeutics, Inc.’s return on equity (ROE) stands at -0.44.